ArticleBreast cancer research and treatment2009
Cyclin E deregulation is an early event in the development of breast cancer.
Article in Breast cancer research and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.Journal of cancer research and clinical oncology · 2023Review
- Long Non-coding RNA SENP3-EIF4A1 Functions as a Sponge of miR-195-5p to Drive Triple-Negative Breast Cancer Progress by Overexpressing CCNE1.Frontiers in cell and developmental biology · 2021Article
- Article
- Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.Nature communications · 2019Article
- The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression.Molecular cancer · 2019Article
- Kinase-independent function of E-type cyclins in liver cancer.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.Oncotarget · 2016Article
- Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.The American journal of pathology · 2016Article
- Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function.American journal of cancer research · 2016Article
- Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Oncotarget · 2015Article
- Article
- Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.Cancers · 2015Review
- Expression of cyclin E in stage III colorectal carcinoma.Oncology letters · 2013Article
- Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.Breast cancer research : BCR · 2012Article
- Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women.PloS one · 2012Article
- Developmental downregulation of Xenopus cyclin E is phosphorylation and nuclear import dependent and is mediated by ubiquitination.Developmental biology · 2011Article
- Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.Cell cycle (Georgetown, Tex.) · 2010Article
- DDX3 regulates cell growth through translational control of cyclin E1.Molecular and cellular biology · 2010Article
- A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.Molecular cancer · 2010Article
- Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.Cancer research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cyclin E has been shown to be overexpressed in some human breast cancers, however, data to support deregulation of cyclin E as an early event in human mammary tumor development is lacking. We analyzed surgical specimens from 183 patients with breast carcinomas and evaluated cyclin E expression in areas of invasive carcinoma, adjacent carcinoma in situ (CIS), and non-neoplastic breast parenchyma. Overexpression of cyclin E was seen in one-third of invasive carcinoma samples, one-third of the CIS component and nearly half of the non-neoplastic breast epithelial cells adjacent to carcinoma (44% vs. 33%, P < or = 0.05). Nuclear labeling for cyclin E was highly concordant between areas of in invasive carcinoma, CIS and non-neoplastic breast epithelial cells from the same patient (P < 0.0001). Localization of cyclin E to the cytoplasm was seen in a small proportion of tumor samples. Our findings suggest that cyclin E deregulation is an early event in the progression from histologically benign mammary epithelial cells to invasive carcinoma and occurs through both overexpression and altered cellular localization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.